Provention Bio EBIT

Provention Bio (PRVB) currently reports a EBIT of $-130M as of December 2022. That compares with $-120M in the prior-year period — down 11.0% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Provention Bio's EBIT history and peer comparisons.

Provention Bio's EBIT decreased from $-120M to $-130M — a 11.0% year-over-year decrease (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Provention Bio's EBIT of $-130M is lower than the Healthcare sector average of $23B. That is roughly 100.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Provention Bio reported $-130M in EBIT as of December 2022. That compares with $-120M in the prior-year period — down 11.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-130M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Provention Bio, and consider following PRVB for alerts when major investors trade the stock.